Most positron emission tomography (PET) imaging studies in head and neck cancer are performed using the radiotracer 18-fluorodeoxyglucose ((18)FDG). PET with FDG has become a standard clinical imaging modality in patients with head and neck cancer. It contributes valuable information in localizing a primary tumor in patients with neck nodal metastases from an unknown primary, in the staging of ...

BACKGROUND (18)FDG-PET plays a significant role in diagnosing malignancy of lung lesions but remains an expensive test available at a limited number of sites in Italy. OBJECTIVE We prospectively compare the diagnostic accuracy of (99m)Tc-MIBI- SPECT and (18)FDG-PET in patients with indeterminate lung lesions to demonstrate that (99m)Tc-MIBI-SPECT may be considered as a valid alternative when ...

Neoadjuvant chemotherapy (NAC) has become a standard therapy for patients with advanced breast cancer. Pathological complete response (pCR) after NAC is an important prognostic indicator, but some patients with pCR continue to experience recurrence. So new predictive and prognostic markers in addition to pCR are needed following NAC for breast cancer. Fluorodeoxyglucose positron emission tomogr...

BACKGROUND For a number of years, FDG-PET was considered as a gold standard for the differential diagnosis of recurrent glioma and radionecrosis. Recently published papers have introduced a wealth of scepticism into this area. The aim of this work is to specify the added value of FDG PET, as compared to MRI, in terms of diagnostics of recurrent gliomas in the clinical setting of the PET Centre ...

OBJECTIVES 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET-CT) is a well-used and established technique for lung cancer staging. Radiation therapy requires accurate target volume delineation, which is difficult in most cases due to coexisting atelectasis. The present study was performed to compare the 18F-FDG PET-CT with contrast enhanced computed tomography...

BACKGROUND Positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) is an accurate method for differentiating benign from malignant disease. The use of FDG-PET for the aetiological diagnosis of pleural disease was investigated in 25 patients. METHODS PET was performed on each subject before invasive procedures were used to determine the aetiological diagnosis. The PET data were ana...

18F-fluorodeoxyglucose ([18F]-FDG) positron emission tomography/computed tomography (PET/CT) is a useful functional image technique to evaluate the disease extent in many cancers, as well differentiate benign from malignant metastasis. We report case of 49-year-old woman with breast cancer and suspected lung metastasis by conventional images. After FDG-PET/CT demonstrating faint, or even no FDG...

we report a case of a 75-year old man that came at hematologist’s attention for lymphoma evaluation due to axillary lymph node enlargement and fever. thorax, abdomen and pelvis contrast-enhanced computed tomography (cect) showed lymph nodes, spleen and liver lesions. axillary lymph node biopsy was performed and the diagnosis of marginal zone lymphoma (mzl) at stage iv was postulated, then the p...

(18)F-Labeled fluorodeoxyglucose positron-emission tomography (FDG-PET), a rapidly evolving functional imaging modality, has recently been shown to be useful in the diagnosis and staging of various malignant tumors due to focal uptake of FDG-labeled glucose in malignant cell populations. However, the role of FDG-PET in the diagnosis and staging of biliary tract cancer is still controversial and...

BACKGROUND Diagnostic guidelines for the use of 2-(fluorine 18) fluoro-2 deoxy-D-glucose (FDG)-positron emission tomography (PET) in cancer screening have yet to be established. We assessed inter-observer variability in screening FDG-PET. METHODS Subjects comprised 40 individuals who underwent FDG-PET and computed tomography (CT) for cancer screening. To assess various patterns of FDG uptakes...